Riociguat

1. Riociguat inhibits MAPK/ERK signalling in mouse cells.

   “Riociguat attenuated RANKL-induced phosphorylation of JNK, ERK, and p38 and reduced PPARγ–PGC-1β association.”

   Cellsin RANKL-stimulated bone marrow-derived macrophages

   Riociguat Suppresses Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Attenuating MAPK Signaling and PPARγ–PGC-1β Coupling

   Research Square·15 Oct 2026Preprint

More on MAPK/ERK signalling

1. Riociguat inhibits osteoclastogenesis in mouse cells.

   “Riociguat inhibited osteoclast formation without detectable cytotoxicity, disrupted F-actin-ring organization, reduced resorption-pit formation”

   Cellsin RANKL-stimulated bone marrow-derived macrophages

   Riociguat Suppresses Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Attenuating MAPK Signaling and PPARγ–PGC-1β Coupling

   Research Square·15 Oct 2026Preprint

1. Riociguat prevents bone loss in mice.

   “In ovariectomized mice, riociguat preserved trabecular microarchitecture and reduced histological indices of osteoclast activity.”

   Animalsin ovariectomized mice

   Riociguat Suppresses Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Attenuating MAPK Signaling and PPARγ–PGC-1β Coupling

   Research Square·15 Oct 2026Preprint

More on Bone loss